<DOC>
	<DOC>NCT01787279</DOC>
	<brief_summary>This is an expanded access programme to make Pegasys (peginterferon alfa-2a) available to patients with HBeAg-negative chronic hepatitis B in Morocco. Patients will receive Pegasys 180 mcg subcutaneously weekly for 48 weeks and efficacy and safety will be recorded during treatment and for 24 weeks of follow-up.</brief_summary>
	<brief_title>An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patients, &gt;/= 18 and &lt;/= 70 years of age HBeAgnegative chronic hepatitis B HBsAgpositive for at least 6 months, anti hepatitis B (HBs) negative Serum alanine transaminase (ALT) &gt; 2 ULN (upper limit of normal) but &lt;/= 10 x Upper limit of normal (ULN) Hepatitis B virus (HBV) DNA &gt; 10'000 copies/ml (Roche Monitor or Taqman) No previous treatment with interferon (standard or pegylated) or with a nucleoside analogue Women of childbearing potential must agree to use reliable contraception during the study and for 3 months after treatment completion Previous antiviral interferonbased therapy for chronic hepatitis B Pregnant and lactating women Evidence of decompensated liver disease Coinfection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV) History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis Previous or current hepatocellular carcinoma History or other evidence of bleeding from oesophageal varices or other conditions consistent with decompensated liver disease Inadequate hematologic or renal function Serum bilirubin level &gt; 2 times the upper limit of normal Severe psychiatric disease History of severe seizure disorder or current anticonvulsant use History of evidence of any disease or condition which would make the patient, in the opinion of the investigator, unsuitable for the study Evidence of drug abuse within one year of study entry Alcohol intake of more than 3 standard drinks per day for men and 2 standard drinks per day for women (1 standard drink contains 10 g of alcohol) Participation in another trial or receipt of an investigational drug within 12 weeks prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>